3. Traditional Diagnostic Approaches

  1. Stefan Faderl MD Associate Professor and
  2. Hagop Kantarjian MD Chairman Professor
  1. Hartmut Koeppen MD, PhD Staff Pathologist1,
  2. Carlos E. Bueso-Ramos MD, PhD Professor2 and
  3. Sergej N. Konoplev MD, PhD2

Published Online: 4 JAN 2011

DOI: 10.1002/9781444327359.ch3

Leukemias: Principles and Practice of Therapy

Leukemias: Principles and Practice of Therapy

How to Cite

Koeppen, H., Bueso-Ramos, C. E. and Konoplev, S. N. (2010) Traditional Diagnostic Approaches, in Leukemias: Principles and Practice of Therapy (eds S. Faderl and H. Kantarjian), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444327359.ch3

Editor Information

  1. Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX, USA

Author Information

  1. 1

    Department of Pathology, Genentech, Inc, South San Francisco, California, USA

  2. 2

    Department of Hematopathology University of Texas MD Anderson Cancer Center Houston, Texas, USA

Publication History

  1. Published Online: 4 JAN 2011
  2. Published Print: 26 NOV 2010

ISBN Information

Print ISBN: 9781405182355

Online ISBN: 9781444327359

SEARCH

Keywords:

  • Bone marrow biopsy;
  • cytochemistry;
  • immunohistochemistry;
  • flow cytometry;
  • karyotype;
  • myeloproliferative neoplasm;
  • acute myeloid leukemia (AML);
  • acute lymphoblastic leukemia (ALL);
  • chronic lymphocytic leukemia (CLL)

Summary

This chapter describes the laboratory diagnostic approach to myeloproliferative neoplasms and acute leukemias, as well as chronic lymphocytic leukemia and related lymphoproliferative disorders. Although significant progress has been made in the immunophenotypic and molecular characterization of these disorders, morphologic evaluation of bone marrow and/or peripheral blood specimens remains a critical component of the diagnostic work-up. We describe the morphologic features of the myeloid and lymphoid disorders relevant to this chapter and highlight microscopic findings that may point toward unique genetic abnormalities. The morphologic evaluation is considered within context of the immunophenotypic analysis by flow cytometry and/or immunohistochemistry and the karyotypic and molecular characterization of the disorder. Individual disease entities are identified using the terminology of the most recent World Health Organization classification of hematopoietic and lymphoid neoplasms, published in 2008.